SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-18-008268
Filing Date
2018-11-01
Accepted
2018-11-01 16:41:18
Documents
57
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20180930x10q.htm 10-Q 1591799
2 EX-31.1 crvs-20180930ex31120ced1.htm EX-31.1 13523
3 EX-31.2 crvs-20180930ex312fd3cea.htm EX-31.2 13460
4 EX-32.1 crvs-20180930ex321edaa43.htm EX-32.1 13628
  Complete submission text file 0001558370-18-008268.txt   5108091

Data Files

Seq Description Document Type Size
5 EX-101.INS crvs-20180930.xml EX-101.INS 1040524
6 EX-101.SCH crvs-20180930.xsd EX-101.SCH 34270
7 EX-101.CAL crvs-20180930_cal.xml EX-101.CAL 46477
8 EX-101.DEF crvs-20180930_def.xml EX-101.DEF 93325
9 EX-101.LAB crvs-20180930_lab.xml EX-101.LAB 318919
10 EX-101.PRE crvs-20180930_pre.xml EX-101.PRE 217764
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 181154404
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1